WO2015183984A3 - Compositions thérapeutiques contenant un tocophérol et leurs utilisations - Google Patents

Compositions thérapeutiques contenant un tocophérol et leurs utilisations Download PDF

Info

Publication number
WO2015183984A3
WO2015183984A3 PCT/US2015/032715 US2015032715W WO2015183984A3 WO 2015183984 A3 WO2015183984 A3 WO 2015183984A3 US 2015032715 W US2015032715 W US 2015032715W WO 2015183984 A3 WO2015183984 A3 WO 2015183984A3
Authority
WO
WIPO (PCT)
Prior art keywords
phe
lys
arg
aromatic
tocopherol
Prior art date
Application number
PCT/US2015/032715
Other languages
English (en)
Other versions
WO2015183984A2 (fr
Inventor
D. Travis Wilson
Mark BAMBERGER
Peter OATES
Original Assignee
Stealth Peptides International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International, Inc. filed Critical Stealth Peptides International, Inc.
Publication of WO2015183984A2 publication Critical patent/WO2015183984A2/fr
Publication of WO2015183984A3 publication Critical patent/WO2015183984A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés et des compositions de traitement et/ou de prévention de maladies ou d'états pathologiques consistant à administrer du tocophérol, et/ou des dérivés ou des analogues de celui-ci d'origine naturelle ou artificielle, ou des sels de celui-ci pharmaceutiquement acceptables, seuls ou en combinaison avec un ou plusieurs agents actifs (p. ex. un peptide aromatique-cationique).<i /> La présente technologie concerne des compositions à base de peptides aromatiques-cationiques liés à un tocophérol, ainsi que des utilisations de ces compositions. Dans certains modes de réalisation, le peptide aromatique-cationique comprend un composé 2',6'-diméthyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2 ou D-Arg-2',6'-Dmt-Lys-Phe-NH2.
PCT/US2015/032715 2014-05-28 2015-05-27 Compositions thérapeutiques contenant un tocophérol et leurs utilisations WO2015183984A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462003757P 2014-05-28 2014-05-28
US62/003,757 2014-05-28

Publications (2)

Publication Number Publication Date
WO2015183984A2 WO2015183984A2 (fr) 2015-12-03
WO2015183984A3 true WO2015183984A3 (fr) 2016-04-07

Family

ID=54700044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/032715 WO2015183984A2 (fr) 2014-05-28 2015-05-27 Compositions thérapeutiques contenant un tocophérol et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2015183984A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3008849A1 (fr) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Derives fluoroalkyle, fluoroalcoxy, phenoxy, heteroaryloxy, alcoxy, et amine 1,4-benzoquinone pour le traitement de troubles du stress oxydatif
US11325943B2 (en) * 2017-06-02 2022-05-10 Stealth Biotherapeutics Inc. Crystalline salt forms of SBT-20
JP2022533837A (ja) * 2019-05-20 2022-07-26 ポビバ コーポレーション 生物活性物質と胆汁酸塩を含む組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153890A1 (en) * 2001-10-05 2005-07-14 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
US20090202481A1 (en) * 2008-02-08 2009-08-13 Qps Llc Composition for Sustained Release Delivery of Proteins or Peptides
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
WO2014022551A1 (fr) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methodes de traitement de l'atherosclerose
US8697657B2 (en) * 2010-03-15 2014-04-15 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153890A1 (en) * 2001-10-05 2005-07-14 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
US20090202481A1 (en) * 2008-02-08 2009-08-13 Qps Llc Composition for Sustained Release Delivery of Proteins or Peptides
US8697657B2 (en) * 2010-03-15 2014-04-15 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
WO2014022551A1 (fr) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methodes de traitement de l'atherosclerose
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same

Also Published As

Publication number Publication date
WO2015183984A2 (fr) 2015-12-03

Similar Documents

Publication Publication Date Title
WO2016004093A3 (fr) Compositions thérapeutiques comprenant des inhibiteurs de la galectine-3 et utilisations de celles-ci
WO2015183963A3 (fr) Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations
WO2015183995A3 (fr) Compositions thérapeutiques comprenant de la frataxine, de la lactoferrine et des enzymes mitochondriales génératrices d&#39;énergie et leurs utilisations
WO2014205317A3 (fr) Peptides cycliques utilisés en tant qu&#39;agents de ciblage de protéines
WO2014165607A3 (fr) Formulations peptidiques cationiques aromatiques, compositions et procédés d&#39;utilisation
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
PH12015502002A1 (en) Tripeptide epoxy ketone protease inhibitors
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
CA3010568A1 (fr) Supports nanofibreux oromumuqueux pour traitement therapeutique
JO3326B1 (ar) مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد
UA111599C2 (uk) Композиція каспофунгіну
NZ759173A (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
WO2015183984A3 (fr) Compositions thérapeutiques contenant un tocophérol et leurs utilisations
MX2022013450A (es) Formulaciones farmaceuticas.
WO2015183985A3 (fr) Compositions thérapeutiques comprenant des naphthoquinones et leurs utilisations
WO2016015798A9 (fr) Composition de film orodispersible, comprenant de l&#39;énalapril pour le traitement de l&#39;hypertension dans une population pédiatrique
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
EP4219534A3 (fr) Procédés de traitement et de prophylatise contre les troubles inflammatoires
NZ719321A (en) Storage stable lyophilized tripeptide formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15800496

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 27.02.2017)

122 Ep: pct application non-entry in european phase

Ref document number: 15800496

Country of ref document: EP

Kind code of ref document: A2